Co-Inventors
Burbelo, Peter (NIDCR)
Ali, Mir (NIAID)
Development Stages
Analytical Assay Performance Stage
Research Products
Research Equipment
Antibodies
The technology described is a sophisticated and high-throughput luciferase immunoprecipitation system (LIPS) assay designed to detect antibodies specific to Varicella-zoster virus (VZV) glycoprotein E (gE). By transfecting cells with VZV protein-Renilla luciferase fusion protein constructs and subsequently performing immunoprecipitations with protein A/G beads, this innovative assay enables the quantitative measurement of VZV gE antibody levels in blood serum samples. Notably, it demonstrates a sensitivity comparable to the established fluorescent antibody to membrane antigen test (FAMA), making it a promising tool for identifying anti-VZV antibodies in individuals who have received the VZV vaccine. However, potential patent challenges may arise due to similarities with assays used for related herpesviruses, and the market for this technology is relatively niche, primarily targeting populations at higher risk of VZV infection, such as pregnant women and healthcare workers.
Commercial Applications
The high-throughput luciferase immunoprecipitation system (LIPS) assay for VZV antibody detection has versatile potential applications. It can be used for vaccine studies, epidemiological research, and clinical diagnostics, offering accurate results similar to the FAMA test. Despite potential patent challenges, it's well-suited for specialized purposes like assessing vaccine responses in pregnant women and screening high-risk healthcare workers. This makes it valuable in focused serological research and diagnostics.
Competitive Advantages
The proposed high-throughput luciferase immunoprecipitation system (LIPS) assay for VZV antibody detection offers key competitive advantages. It provides quantitative results, enables efficient screening of numerous samples, and matches the sensitivity of the established FAMA test. While patent challenges may arise, this technology serves niche markets, like pregnant women and healthcare workers at higher risk of VZV exposure, making it a valuable tool for focused serological diagnosis and research.
